Join us as Dr. Shelley Hwang (Principal Investigator) and Deborah Collyar (Patient Advocate) discuss the initial results from the low-risk DCIS study called Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET), which was presented at the San Antonio Breast Cancer Symposium in December 2024.
Key Takeaways:
- At two years, women with low-risk DCIS randomized to active monitoring had a non-inferior rate of invasive cancer in the ipsilateral breast compared to those randomized to guideline concordant care
- Short-term results are encouraging, and additional follow up will determine the long-term feasibility of this approach
- Active monitoring for DCIS seemed to yield better (or certainly no worse) outcomes than surgical treatment. Therefore, there is no need to rush treatment decisions.
